Impact Healthcare
REIT plc

Interim results for the period to
30 June 2019
Agenda

- Company first half overview
- Our market
- Portfolio overview
- Asset acquisitions and active asset management
- Key financials
- Conclusion and outlook
- Q&A

Presentation team – Investment Manager

- **Andrew Cowley, Managing Partner**
  20 years’ experience managing listed and unlisted funds investing in infrastructure, real assets and private equity for Macquarie and Allianz

- **Mahesh Patel, Managing Partner**
  30 years’ successful experience investing in, owning and operating care homes. Qualified chartered accountant

- **David Yaldron, Finance Director**
  Qualified at KPMG as a chartered accountant. Real estate investment experience gained at Grosvenor and Europa Capital
Company first half overview
Company overview

▪ Impact is a specialist REIT, which invests in UK-only healthcare real estate assets that our tenants use to provide essential services to their communities

▪ At 30 June 2019 Impact owned 81 properties, operated by eight tenants who pay us rent of £21.6 million per annum

▪ 100% of leases are inflation-linked. WAULT 19.6 years

▪ Successful delivery on new progressive dividend and total return target policies introduced at the beginning of 2019

▪ Proceeds from over-subscribed £100 million equity placing in May 2019 now 85% committed

▪ Strong first half results give company good momentum going into H2
H1 2019 operational highlights

Number of properties
- H1 2018: 63
- H1 2019: 81
  +29%

Number of tenants
- H1 2018: 4
- H1 2019: 8
  +100%

Contracted rent roll (£ million)
- H1 2018: 14.5
- H1 2019: 21.6
  +49%

Portfolio value (£ million)
- H1 2018: 184.3
- H1 2019: 271.6
  +47%
H1 2019 financial highlights

- **Profit before tax**: £8.5 million in H1 2018, £10.9 million in H1 2019, +29%
- **EPRA earnings per share**: 3.23 pence in H1 2018, 3.62 pence in H1 2019, +12%
- **Dividends declared**: 3.00 pence in H1 2018, 3.09 pence in H1 2019, +3%
- **Total expense ratio**: 1.71% in H1 2018, 1.51% in H1 2019, -12%
- **NAV per share**: 102.0 pence in H1 2018, 104.7 pence in H1 2019, +3%
- **Loan to value**: 11.2% in H1 2018, 7.7% in H1 2019, -31%
H1 2019 financing highlights

- 1.5p per share dividend declared
  NAV 103.18p per share
- £200m Placing Programme announced
  Migration to Premium Listing on the Main Market
- 1.5425p per share dividend declared
  NAV 104.18p per share
- IHR to be included in FTSE EPRA/NAREIT Index
- Over-subscribed £100m equity placing closes priced at 106p
- New £25m loan facility
- 1.5425p per share dividend declared
  NAV 104.67p per share

Share price range: 100.00 - 116.00

Post balance sheet highlights

- Completed the acquisition of three homes which are now leased to existing tenants: Holmesley in Devon and Argentum in North Somerset, both leased to Welford; and Old Prebendal House in Oxfordshire leased to Careport

- Exchanged contracts to acquire two homes in Suffolk (Baylham and Barham) leased to our ninth tenant, Optima Care

- Once completed, these acquisitions will increase our number of properties to 86 and grow our contracted rent roll from £21.6 million at 30 June 2019, to £23.8 million
Our market
Growing demand for elderly care

- People aged over 85, the age group most likely to need care, are the fastest growing segment of the population.

- Number of people over 85 in the UK forecast to double by 2041, from 1.6 million in 2016 to 3.2 million.

- At the moment around 15% of people aged over 85 require a level of care which can only be provided in a hospital or a care home.

Source: Office for National Statistics
While capacity has declined by 17% from its peak in 1996.

Capacity has declined over 20 years
Number of average care beds for the elderly (000)

- Independent sector care homes
- NHS geriatric and EMI hospital long-stay
- Local authority and NHS care homes

Source: LaingBuisson database
A growth market for providers of care

Market value of independent sector (£m 000)
Nursing and residential care of older people provided by the independent sector

Source: LaingBuisson database and official sources
Portfolio review
Portfolio overview

Long-dated and inflation-linked income and capital growth from UK healthcare real estate

81 Care homes¹
>4,000 Beds across the UK
£21.6m Contracted rent²
19.6 years Weighted average unexpired lease term
8 tenants National and strong local operators

¹ Includes two medical units leased to the NHS. Does not include 4 homes exchanged post balance sheet
² As at 30th June 2019
Strong lease structures

Strong lease structures generate attractive, predictable and long term income:

- Long fixed term: Minster, Croftwood, and Welford 20 years; all other tenants 25 years
- Options to extend
- No break clauses
- Upwards only annual rent reviews at RPI, with a floor of 2% and cap of 4%
- Full repairing and insuring leases
- Tenants responsible for maintaining homes and have committed to a minimum level of expenditure per bed on maintenance annually, rising with RPI
- Penalties if rent cover falls below agreed levels and ability to change the tenant for under-performance even if rent has been paid in full
# Robust operating performance from existing tenants

<table>
<thead>
<tr>
<th>Metric</th>
<th>Impact¹</th>
<th>National average²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of homes</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Rent cover</td>
<td>1.8x</td>
<td></td>
</tr>
<tr>
<td>(tenant EBITDARM/rent)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6M to June 2019</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CQC ratings³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outstanding</td>
<td>6.3%</td>
<td>4.2%</td>
</tr>
<tr>
<td>Good</td>
<td>68.4%</td>
<td>72.2%</td>
</tr>
<tr>
<td>Requires Improvement</td>
<td>24.1%</td>
<td>21.5%</td>
</tr>
<tr>
<td>Inadequate</td>
<td>1.3%</td>
<td>2.1%</td>
</tr>
<tr>
<td>Portfolio net initial yield</td>
<td>7.5%</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ Data as at 30 June 2019 unless otherwise stated  
² Source: CQC register of homes in England with more than 30 beds  
³ As at 1 August 2019
Asset acquisitions and active asset management
Disciplined asset acquisition programme

(Net initial yield)

- Minster seed portfolio¹
- Croftwood seed portfolio¹
- Prestige (Jan 2018)
- Welford (Mar 2018)
- Careport (Sep 2018)
- Renaissance (Nov 2018)
- MMCG (May 2019)
- Careport and NHS (June 2019)
- Welford (June 2019)
- Optima (August 2019)³

Source: Company information

¹ Minster and Croftwood are both part of the Minster Group
² Net Initial Yield defined as rental income at acquisition divided by purchase price net of acquisition costs
³ Contracts exchanged post 30th June 2019 balance sheet
The investment opportunity

465,000 beds available for residential elderly care

£16.9 billion spent on residential elderly care in year to April 2018

90% of available beds provided by private sector

Source: CBRE United Kingdom Healthcare Update and LaingBuisson
Attractive investment pipeline

- Disciplined approach to new acquisitions in the area of opportunity we have defined

- Strong focus on quality of new tenants. We are looking for:
  - Track record of providing good quality care
  - Consistent operating margins
  - Strong balance sheet
  - Experience of improving homes
  - Ambitious to expand in partnership with us

- When we raised new equity in May 2019 we said we were working on 12 transactions, five of which have now been executed

- We are at an advanced stage on four transactions which, if completed, would add a further 15 homes and two new tenants to the portfolio

- There can be no certainty that any of these transactions will complete

- However, we remain confident of the potential to identify new assets which will be accretive and will continue to diversify the portfolio
Our asset management strategy

- Asset management is one of the most attractive strategies we have to deploy capital
- It offers a potential win-win-win:
  - New, high-quality accommodation for residents
  - Higher earnings and better rent cover for our tenants
  - Repositioned building for Impact with higher rent and potential for capital gains
- Risks lower and easier to analyse than greenfield development
- We already own the land and tenant has central services (staff offices, kitchens, laundries) on site reducing the marginal cost of adding beds
- Financial arrangements for our funding of capex are set out in the framework agreements we have in place with tenants
- Yield on capital deployed > 8% per annum
Adding value through active asset management

Freeland House, Oxfordshire
- 46-bed extension linked to existing home
- New beds will provide dementia care while existing home continues to offer nursing beds
- Capex £4.9 million
- Central double volume atrium and access to new landscaped gardens to give residents secure and high quality day space
- Due to complete in December 2019

Diamond House, Leicester
- 30-bed extension linked to existing home
- New beds will provide dementia care while existing home continues to offer nursing beds
- Capex £2.7 million
- Practical completion achieved in August 2019
- New beds will come into operation once they have been registered with the CQC
### Active asset management pipeline

- So far 107 new beds delivered and in operation at five homes. Practical completion of 30 beds at Diamond House in August 2019, awaiting CQC registration before becoming operational.
- Major project at Freeland progressing well.
- Asset managers working on projects at ten additional homes.

<table>
<thead>
<tr>
<th>Home</th>
<th>Tenant</th>
<th>Capex (£m)</th>
<th>Beds added</th>
<th>Rent increase (£k)</th>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turnpike</td>
<td>Croftwood</td>
<td>0.92</td>
<td>25</td>
<td>78</td>
<td>Completed</td>
<td>Conversion of closed supported living unit to care beds</td>
</tr>
<tr>
<td>Littleport</td>
<td>Minster</td>
<td>2.17</td>
<td>21</td>
<td>185</td>
<td>Completed</td>
<td>Development of a new dementia unit</td>
</tr>
<tr>
<td>Ingersley</td>
<td>Croftwood</td>
<td>0.20</td>
<td>12</td>
<td>16</td>
<td>Completed</td>
<td>Conversion of closed supported living unit to care beds</td>
</tr>
<tr>
<td>Parkville II</td>
<td>Prestige</td>
<td>2.17¹</td>
<td>38</td>
<td>188</td>
<td>Completed</td>
<td>Conversion of a closed building to a new dementia unit</td>
</tr>
<tr>
<td>Garswood</td>
<td>Croftwood</td>
<td>1.10</td>
<td>11</td>
<td>106</td>
<td>Completed</td>
<td>Reconfiguration and extension of home</td>
</tr>
<tr>
<td>Diamond House</td>
<td>Minster</td>
<td>2.65</td>
<td>30</td>
<td>228</td>
<td>Completed</td>
<td>Development of a new dementia unit</td>
</tr>
<tr>
<td>Freeland</td>
<td>Minster</td>
<td>4.85</td>
<td>46</td>
<td>403</td>
<td>Underway</td>
<td>Development of a new dementia unit</td>
</tr>
<tr>
<td>Loxley</td>
<td>Croftwood</td>
<td>0.60</td>
<td>5</td>
<td>48</td>
<td>Ready to start</td>
<td>Reconfiguration and extension of home</td>
</tr>
<tr>
<td>Old Prebendal House</td>
<td>Careport</td>
<td>0.75</td>
<td>N/A</td>
<td>60</td>
<td>Underway</td>
<td>Reconfiguration and improvements to home</td>
</tr>
<tr>
<td>Amberley, Craigend,</td>
<td>Minster</td>
<td>0.69</td>
<td>N/A</td>
<td>55</td>
<td>Underway</td>
<td>Enhancement of day spaces and bathrooms</td>
</tr>
<tr>
<td>Duncote Hall and Falcon</td>
<td>Careport</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Total** | **16.10** | **1,367**

¹ Estimated deferred payment
Conclusion and outlook
Building blocks of NAV total return

- **Dividend yield**
  - Target 6.17p per share

- **Rental growth**
  - 2-4% p.a. RPI

- **Asset management**
  - 1% + p.a.

---

1 All figures in this analysis are based on Investment Manager assumptions. The target dividend and target total return are targets only and not a profit forecast. There can be no assurance that the target dividend or target total return will be achieved and investors should place no reliance on such targets when making an investment decision.
Good momentum to continue to deliver our business model

- Efficient corporate structure
- Disciplined capital allocation
- Strong balance sheet
- Active asset management
- Target NAV total return 9% p.a.
Appendices
### Statement of comprehensive income

<table>
<thead>
<tr>
<th>(£’000)</th>
<th>For the six months ended</th>
<th>Variance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30 June 2019</td>
<td>30 June 2018</td>
</tr>
<tr>
<td>Net rental income</td>
<td>10,814</td>
<td>7,864</td>
</tr>
<tr>
<td>Administration and other expenses</td>
<td>(2,051)</td>
<td>(1,644)</td>
</tr>
<tr>
<td><strong>Operating profit before changes in fair value</strong></td>
<td><strong>8,763</strong></td>
<td><strong>6,220</strong></td>
</tr>
<tr>
<td>Changes in fair value of investment properties</td>
<td>3,416</td>
<td>2,339</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td><strong>12,179</strong></td>
<td><strong>8,559</strong></td>
</tr>
<tr>
<td>Net finance expenses</td>
<td>(913)</td>
<td>(83)</td>
</tr>
<tr>
<td>Changes in fair value of interest rate derivatives</td>
<td>(320)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Profit before taxation</strong></td>
<td><strong>10,946</strong></td>
<td><strong>8,476</strong></td>
</tr>
</tbody>
</table>

**Earnings per share**                                        | 5.05p                    | 4.41p    |
**EPRA earnings per share**                                   | 3.62p                    | 3.23p    |
**Adjusted earnings per share**                               | 2.58p                    | 2.37p    |
**Dividend declared for the year**                            | 3.09p                    | 3.00p    |
# Statement of financial position

<table>
<thead>
<tr>
<th>(£’000)</th>
<th>As at 30 June 2019</th>
<th>As at 31 December 2018</th>
<th>Variance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment property (independent market value)</td>
<td>271,617</td>
<td>223,845</td>
<td>21.3%</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>52,147</td>
<td>1,470</td>
<td></td>
</tr>
<tr>
<td>Other assets</td>
<td>1,693</td>
<td>1,064</td>
<td></td>
</tr>
<tr>
<td>Bank borrowings</td>
<td>(23,272)</td>
<td>(24,709)</td>
<td></td>
</tr>
<tr>
<td>Other liabilities</td>
<td>(2,255)</td>
<td>(3,333)</td>
<td></td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td><strong>299,930</strong></td>
<td><strong>198,337</strong></td>
<td>51.2%</td>
</tr>
</tbody>
</table>

**Investment property:**

<table>
<thead>
<tr>
<th></th>
<th>£’000</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>31 Dec 2018</strong></td>
<td><strong>223,845</strong></td>
</tr>
<tr>
<td>Acquisitions</td>
<td>39,465</td>
</tr>
<tr>
<td>Capital improvements</td>
<td>3,152</td>
</tr>
<tr>
<td>Revaluation movement</td>
<td>5,155</td>
</tr>
<tr>
<td><strong>30 June 2019</strong></td>
<td><strong>271,617</strong></td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net asset value per share</td>
<td>104.67p</td>
</tr>
<tr>
<td>EPRA net asset value per share</td>
<td>104.62p</td>
</tr>
<tr>
<td>Net asset value Total Return (^1)</td>
<td>4.39%</td>
</tr>
<tr>
<td>Loan to Value</td>
<td>7.7%</td>
</tr>
</tbody>
</table>

\(^1\) Net asset value Total Return calculated using EPRA BVI as at 30 June 2019 for the year ended 30 June 2019.
## NAV bridge

<table>
<thead>
<tr>
<th>Date</th>
<th>EPRA earnings</th>
<th>Change in fair value of portfolio</th>
<th>Change in fair value of derivative</th>
<th>Q4 2018 dividend</th>
<th>Q1 2019 dividend</th>
<th>Net equity placing proceeds</th>
<th>Jun 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dec 2018</td>
<td>198.3</td>
<td>7.9</td>
<td>3.4</td>
<td>-0.3</td>
<td>-2.9</td>
<td>-4.4</td>
<td>98.0</td>
</tr>
<tr>
<td>Jun 2019</td>
<td>299.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **103.2 pence per share** (192.2 million shares in issue)
- **104.7 pence per share** (286.5 million shares in issue)
| Term sheet |
|-----------------|-----------------|
| **Issuer** | • Impact Healthcare REIT PLC |
| **Market** | • Listed on the specialised fund segment of the Main Market of London Stock Exchange on 7 March 2017, transferred to the premium segment of the Official List on 8th February 2019 |
| **Current share capital** | • 286,546,454 ordinary shares outstanding |
| **Target dividend** | • Target dividend of 6.17 pence per share for 2019. |
| **Gearing** | • The Company utilises prudent financing with a maximum LTV of 35% of gross assets |
| **Valuation** | • Quarterly valuation by Cushman & Wakefield |
| **Independent Board** | • Board comprised of 5 experienced Non-Executive Directors and is independent of the AIFM |
| **Placing programme** | • Prospectus for a placing programme of up to 200 million new ordinary shares published on 11 February 2019. 100 million new shares placed at 106 pence per share in May 2019 |
| **Discount control** | • Share buy-back authority for up to 14.99% of issued share capital. |
| **AIFM** | • Impact Health Partners LLP – Principals: Mahesh Patel and Andrew Cowley |
| **Management commitment** | • Mahesh Patel £10m share holding in the Company. Other members of management and board hold £0.9m |
| **Fees** | • Management fees: 1% of NAV payable to Impact Health Partners LLP reducing to 0.70% on NAV above £500m |
| **Corporate brokers and other advisers** | • Winterflood Securities, RBC, Travers Smith and BDO |
Impact board and company structure

The five experienced Non-Executive directors comprising the board provide strong corporate governance and close alignment to shareholders via a significant shareholding

- **Chairman:** Rupert Barclay (independent non-executive)
  - Chairman of Sanditon Investment Trust and ex-chairman of audit committee of Lowland Investment Co. Ex-member of the Remco and audit committees of Instinet Group Inc.
  - Qualified accountant, INSEAD MBA and Cambridge MA

- **Director:** Amanda Aldridge (independent non-executive)
  - Former audit and advisory partner at KPMG LLP
  - Extensive audit and advisory work including clients with significant property portfolios.
  - Chartered accountant

- **SID:** Rosemary Boot (independent non-executive)
  - Former Executive Director of Circle Housing Group and Finance Director of the Carbon Trust. 16 years corporate finance experience at UBS Warburg. Currently non-executive director of Southern Water
  - Cambridge MA

- **Director:** Paul Craig (non-executive)
  - Portfolio manager at Old Mutual Global Investors. Over 20 years of investment experience
  - Old Mutual Global Investors has a 20.6% interest in the Company through funds managed by Paul

- **Director:** Philip Hall (independent non-executive)
  - Formerly chairman of Jones Lang LaSalle’s healthcare team in the UK. 20+ years’ experience in the healthcare sector internationally. In 2011 acted for landlords in the restructuring of Southern Cross
  - Chartered Surveyor with further qualifications in environmental sciences and town planning

---

Source: Company information

1 As at 25 October 2018
2 Minster and Croftwood are both part of the Minster Group
Disclaimer

This document has been prepared for information purposes only by Impact Healthcare REIT plc (the "Company") for use in connection with preliminary discussions relating to the Company. This document is not and should not be construed as a prospectus or offering document and recipients should not subscribe for any shares in, or make any investment decision in relation to the Company on the basis of the information in this document. Any investment decision to subscribe for new shares in the Company must be made exclusively on the basis of a prospectus or other offering document prepared by the Company, which will be provided to you and will supersede the information in this document. Copies of a prospectus, if published, will be available from www.impactreit.uk.

Nothing in this document constitutes investment advice nor does it constitute a recommendation and nothing contained in this document should be deemed to have been based upon a consideration of the investment objectives, financial situation or particular needs of any specific recipient.

This document is an advertisement and not a prospectus and is strictly confidential, may not be distributed to the press or any other person, may not be reproduced in any form and may not be published, in whole or in part, for any purpose. Failure to comply with this restriction may constitute a violation of applicable securities laws.

The information and opinions contained in this document are provided as at the date of the document and are subject to change. No representation or warranty, express or implied, is or will be made in relation to the accuracy or completeness of the information contained herein and, save in the case of fraud, no responsibility or liability (whether direct or indirect, in contract, tort or otherwise) is or will be accepted by the Company, Impact Health Partners LLP, Carne Global AIFM Solutions (C.I.) Limited, Winterflood Securities Limited, RBC Europe Limited or by any of their respective directors, partners, officers, employees, or any member of their respective group of companies or advisers ("Affiliates") in relation thereto.

All projections, estimations, target returns and the like in this document are illustrative exercises involving significant elements of judgement and analysis and using the assumptions described herein, which assumptions, judgements and analyses may or may not prove to be correct. The actual outcome may be materially affected by changes in, for example, economic and/or other circumstances. Each of the Company, Impact Health Partners LLP, Carne Global AIFM Solutions (C.I.) Limited, Winterflood Securities Limited, RBC Europe Limited, their respective Affiliates and their respective directors, officers, employees, representatives and agents expressly disclaims any and all liability which may be based thereon. In particular, no representation or warranty is given as to the achievement or reasonableness of future projections, estimates, or target returns, if any. Any views contained herein are based on financial, economic, market and other conditions prevailing as of the date of this document. The information contained in this document will not be updated.

This document may not be published, distributed or transmitted by any means or media, directly or indirectly, in whole or in part, in or into the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The securities mentioned herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and will not be offered, sold, exercised, resold, transferred or delivered, directly or indirectly, in or into the United States or to, or for the account or benefit of, any US person (as defined under Regulation S under the US Securities Act). The Company has not been, and will not be, registered under the U.S. Investment Company Act of 1940, as amended.

Neither this document nor any copy of it may be: (i) taken or transmitted into or distributed in any member state of the European Economic Area (other than the United Kingdom and the Republic of Ireland), Canada, Australia or the Republic of South Africa or to any resident thereof, or (ii) taken or transmitted into or distributed in Japan or to any resident thereof. Any person to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this document in other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

This document has not been approved by an authorised person in accordance with section 212(2)(b) of the Financial Services and Markets Act 2000. Accordingly, in the United Kingdom, this document is being made available to and is directed only at: (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO"); (ii) high net-worth companies, unincorporated associations of individuals with professional experience in matters relating to investments, or other bodies of persons, within the meaning of Article 19 of the FPO; and (iii) persons to whom it is otherwise lawful to provide the financial promotion. The investment or investment activity to which this document relates is available only to such persons and will be engaged in only with such persons. Persons who fall outside categories (i) and (ii) above must check that they fall within category (iii). If they do not, they may not receive this document or attend any meeting relating to its content. Any person who does not fall within categories (i) to (iii) above may not rely on or act upon the matters communicated in this document. Any person falling outside categories (i) to (iii) who has received this document must return it immediately.

Notice to prospective investors in the Netherlands:
The shares (including the rights representing an interest in the shares in global form) in the capital of the Company, have not been and shall not be offered, sold, transferred or delivered in the Netherlands other than to individuals or (legal) entities in the Netherlands who or which qualify as qualified investors (gekwalificeerde beleggers) within the meaning of section 1:1 of the Dutch Act on Financial Supervision (Wet op het financieel toezicht) as amended from time to time. No approved prospectus is required to be published in accordance with the Prospectus Directive (Directive 2003/71/EC), as amended.

Winterflood Securities Limited, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, and RBC Europe Limited (trading as RBC Capital Markets), which is authorised by the Prudential Regulatory Authority and authorised and regulated by the Financial Conduct Authority in the United Kingdom, are acting only for the Company in connection with the matters described in this document and neither Winterflood nor RBC Capital Markets are acting for or advising any other person, or treating any other person as its client, in relation thereto and will not be responsible for providing the regulatory protection afforded to clients of Winterflood nor RBC Capital Markets respectively or advice to any other person in relation to the matters contained herein. None of Winterflood, RBC Capital Markets nor any of their respective Affiliates of agents accepts any responsibility or liability whatsoever for this document, its contents or otherwise in connection with it or any other information relating to the Company, whether written, oral or in a visual or electronic format.

By accepting this document you agree to be bound by the foregoing provisions, limitations and conditions and, in particular, you have represented, warranted and undertaken that you have read and agree to comply with the contents of this notice including without limitation the obligation to keep the information given at the presentation and in this document and its contents confidential.